My guess is that the market is not favorable for
secondary offerings. I have noticed in various press
releases that biotech companies are trying to be creative
when trying to raise capital.
The plus to this
scenario is that the interest which is owed can be
expensed every year even though it isn't paid until the
notes are due at some future time. So I guess this help
the bottom line (Profit figure).
shares would lower the earning per share figure if
everything stayed the same. But I think their drug is really
going to take off. I read an article that appeared in
the newly released issue of the Journal of
Oncology(January 99). They just completed a study using the IDEC
antibody in combination with chemotherapy. The got an
overall response rate of nearly 100%. 55% of the patients
experienced complete remissions while 40% experienced
experienced partial remissions. This is better than the
antibody therapy alone. Just wait until the Oncologist
start using this new treatment. It going to start
selling like water.
I believe there is a lot of this going on the
clinicians' offices already - that is, using Rituxan with
standard chemotherapy. My oncologist told me that after a
regimen of CHOP for newly diagnosed NHL (a standard chemo
treatment), he and his group are "maintaining" their patients
on Rituxan. This is very similar to the trial
currently under way, whose good results you cited. His
group loves Rituxan and they're using it every which
way - never mind what the label says. I believe this
is what was alluded to in the Lehman report which
stated that they expect greater penetration of the
market, due to more off-label use, among other things.
You mentioned an article in "Journal of
Oncology(January 99)". Is this the article you meant?
McLaughlin P, et al.
Clinical status and optimal use of
rituximab for B-cell lymphomas.
1998 Dec;12(12):1763-9; discussion 1769-77, 1781.
If not could you provide an author name and the
exact title and/or journal name, so I can find it? Much
Then you may want to rummage through old annual
reports for idph to get clues on how the deal was done.
But companies don't exactly have to tell the truth,
the whole truth, and nothing but the truth on these
I'm trying to get a handle on how a company
forges an agreement to market a drug and Rituxan is very
similar (monoclonal antibody used to fight cancer) in
nature to another drug that is building up to this point
- and eventual FDA approval.
Rituxan, previously know as the C2B8 antibody, is a
single-agent monoclonal antibody therapy for the treatment of
relapsed or refractory low-grade or follicular,
CD20-positive B-cell non-Hodgkin's lymphoma.
LDP-03, is a humanized monoclonal antibody to the
leukocyte antigen CAMPATH, which is for the treatment of
chronic lymphocytic leukemia ("CLL"). LDP-03 combats CLL
by selectively depleting lymphocytes while sparing
hematopoietic stem cells.
This selective depletion
permits the body to retain needed hematopoietic stem
cells that are the precursors to, and repopulate the
blood with, leukocytes and preserve normal immune
function. LDP-03 binds to the antigen CD52, which is
expressed almost exclusively on lymphocytes and which is
not expressed on hematopoietic stem cells, and
destroys the lymphocytes.
By attacking the antigen
CD52 and its lymphocytes, LDP-03 is more selective
than currently approved drugs for lymphomas and
leukemias which indiscriminately deplete rapidly-dividing
cells, including both lymphocytes and hematopoietic stem
From the BobLLL archives...
First New Drug for Non-Hodgkin's Lymphoma in Decade
Receives FDA Clearance for Marketing
Monoclonal Antibody for Therapeutic Use in Cancer
DIEGO and SOUTH SAN FRANCISCO, Calif.--(BW
HealthWire)-- Nov. 26, 1997--IDEC Pharmaceuticals Corporation
(NASDAQ:IDPH - news) and Genentech, Inc. (NYSE:GNE - news)
today announced that RITUXAN(TM) (Rituximab) has been
cleared for marketing by the U.S. Food and Drug
Administration (FDA). Rituxan, previously know as the C2B8
antibody, is a single-agent monoclonal antibody therapy for
the treatment of relapsed or refractory low-grade or
follicular, CD20-positive B-cell non-Hodgkin's lymphoma.
. . .
It is expected to be commercially
available for use within approximately three weeks.
I don't remember if
this press release was on the exact day of FDA
approval, but very close. Actually the FDA essentially
approved it a couple months earlier, as to medical
criteria, but full approval was delayed until some
manufacturing issues were resolved to FDA approval.
bear in mind that most HMO and insurance companies
have their own procedures for deciding what they will
pay for. I check with my own very large HMO and was
told this process takes 3 to 6 months after FDA
approval. A persistant patient could bypass the procedure
and get it sooner, but they would have to be, well,
I mention all this as it affected early
sales numbers, since I don't know "where you are going
with this." Do let us know.
Now, can anyone tell me when Rituxan gained FDA
approval and when it was first available to
I'm going somewhere with this, so please bear with
me. I'll fill you in later - as I gain more knowledge
about this drug and the company.
I saw on
Comapny Sleuth where IDECPHARM.COM was registered to IDPH
so I'm going out to the net to see is they have a
homepage where I can gather some of this information
In the meantime, thanks to those of you who